Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Choosing the right guide to retirement planning is crucial for your future. Learn essential steps to secure a comfortable retirement.
22,974 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
The Supreme Court will hear a Boulder County climate-liability case against major oil producers, a move that could re...
Beijing and Hong Kong unveiled a coordinated package to deepen offshore yuan liquidity and gold settlement, signaling...
ONEOK posted robust Q4 2025 results, boosting full-year EBITDA, trimming debt, and highlighting synergies from recent...
A tight group of U.S.-listed power chip stocks built around silicon carbide and GaN technologies are rallying as elec...
Keysight Technologies surged to an all-time high after posting a stronger-than-expected Q1 FY2026, driven by AI infra...
A fresh recall of magsafe battery chargers recalled details new fire hazards linked to lithium-ion cells, with refund...
Tempus AI is set to report quarterly earnings after the close, with investors watching for growth signals and profita...
Adobe has pulled back about 40% from its peak, but new AI-driven products and expanding ARR are reinvigorating the bu...
When NVIDIA reports earnings on Feb. 25, investors will scan every line for AI demand signals, margin trends, and gui...
Jim Cramer's ongoing Nvidia purchases rest on one core belief: the CUDA software moat that underpins Nvidia's AI lead...
TJX posted a strong fourth quarter ahead of expectations, yet conservative guidance sparked a pullback in shares as i...